Recent Developments Pertaining to H. pylori Infection

Am J Gastroenterol. 2021 Jan 1;116(1):1-3. doi: 10.14309/ajg.0000000000001031.
No abstract available

MeSH terms

  • Adenocarcinoma / etiology
  • Adenocarcinoma / microbiology
  • Adenocarcinoma / prevention & control
  • Amoxicillin / therapeutic use
  • Antacids / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Bismuth / therapeutic use
  • Clarithromycin / therapeutic use
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Helicobacter Infections / complications
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori
  • Humans
  • Metronidazole / therapeutic use
  • Microbial Sensitivity Tests
  • Omeprazole / therapeutic use
  • Practice Guidelines as Topic
  • Proton Pump Inhibitors / therapeutic use*
  • Pyrroles / therapeutic use
  • Rifabutin / therapeutic use
  • Stomach Neoplasms / etiology
  • Stomach Neoplasms / microbiology
  • Stomach Neoplasms / prevention & control
  • Sulfonamides / therapeutic use
  • Tetracycline / therapeutic use
  • Treatment Outcome

Substances

  • 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
  • Antacids
  • Anti-Bacterial Agents
  • Proton Pump Inhibitors
  • Pyrroles
  • Sulfonamides
  • Metronidazole
  • Rifabutin
  • Amoxicillin
  • Tetracycline
  • Clarithromycin
  • Omeprazole
  • Bismuth